Table 3.
145 patients | 157 patients | |||
PFS | OS | |||
HR (95% CI) | P value | HR (95% CI) | P value | |
Age at first ASCT | 1.1 (0.93 to 1.31) | 0.24 | 1.21 (1.02 to 1.43) | 0.029 |
Histology | ||||
Leiomyosarcoma (reference) | ||||
Liposarcoma | 0.86 (0.43 to 1.72) | 0.67 | 0.75 (0.37 to 1.55) | 0.44 |
Synovial sarcoma | 1.2 (0.63 to 2.26) | 0.58 | 1.4 (0.72 to 2.72) | 0.32 |
Angiosarcoma | 1.24 (0.66 to 2.32) | 0.50 | 1.25 (0.64 to 2.47) | 0.51 |
Other sarcoma | 1.24 (0.76 to 2.01) | 0.40 | 1.11 (0.65 to 1.89) | 0.70 |
Remission status prior ASCT | ||||
CR/NED (reference) | ||||
PR+SD | 1.49 (0.92 to 2.41) | 0.10 | 1.48 (0.87 to 2.53) | 0.15 |
PD | 2.78 (1.62 to 4.77) | 0.0002 | 3 (1.69 to 5.32) | 0.0002 |
Preparative regimen | ||||
Platinum based (reference) | ||||
Melphalan based | 0.61 (0.38 to 0.97) | 0.036 | 0.85 (0.52 to 1.4) | 0.53 |
Other | 0.7 (0.41 to 1.22) | 0.21 | 1.2 (0.68 to 2.13) | 0.52 |
Bold numbers denote statistical significance (p < 0.05).
ASCT, autologous stem cell transplantation; CR, complete remission; NED, no evidence of disease; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial remission; SD, stable disease.